Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A12 | P48065 | 1/20 | 0.36 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.35 |
| ▸ | FABP4 | P15090 | 1/20 | 0.33 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.32 |
| ▸ | PANK3 | Q9H999 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4649045 | 0.86 | POLB (0.41) | SLC6A12FABP4FABP5LMNAHTT | |
| SCHEMBL4650346 | 0.80 | TUBB4A (0.47) | SLC6A12NPC1RAB9ALMNAPOLB | |
| SCHEMBL18921611 | 0.80 | HCRTR1 (0.38) | SLC6A12FABP4FABP5 | |
| SCHEMBL1969832 | 0.77 | HSD11B1 (0.57) | HSD11B1LMNAHTT | |
| SCHEMBL1969860 | 0.76 | KMT2A (0.53) | SLC6A12NPC1RAB9ALMNAHTT | |
| SCHEMBL29375536 | 0.72 | SLC6A12 (0.38) | SLC6A12LMNAGAANAPRT | |
| SCHEMBL671978 | 0.72 | SLC6A12 (0.38) | SLC6A12LMNAGAANAPRT | |
| SCHEMBL13271403 | 0.71 | HSD11B1 (0.43) | SLC6A12HSD11B1RAB9ATDP1 | |
| SCHEMBL28786268 | 0.71 | ALDH1A1 (0.37) | L3MBTL1GAANAPRT | |
| SCHEMBL4650496 | 0.71 | CNR2 (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8673938-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2014-03-18 | — | — | US | disclosed |
| CN-101787016-B | Pyridine carboxamides as 11-beta-hsd1 inhibitors | ASTRAZENECA AB | 2013-08-28 | — | — | CN | disclosed |
| EP-2233480-B1 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-05-29 | — | — | EP | disclosed |
| CN-102603711-A | Pyridine carboxamides as 11-beta-hsd1 inhibitors | ASTRAZENECA AB | 2012-07-25 | — | — | CN | disclosed |
| CN-101573336-B | Pyridine carboxamides as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2012-03-21 | — | — | CN | disclosed |
| US-7964618-B2 | 2-[(3R)-1-[5-(cyclohexylcarbamoyl)-6-propylsulfanyl-pyridin-2-yl]-3-piperidyl]acetic acid, for example; compounds possess human 11- beta-hydroxysteroid dehydrogenase type1 enzyme (11 beta HSD1) inhibitory activity and accordingly have value in treatment of disease states including metabolic syndrome | ASTRAZENECA AB (SE) | 2011-06-21 | — | — | US | disclosed |
| EP-2233480-A1 | Chemical compounds | AstraZeneca AB (SE) | 2010-09-29 | — | — | EP | disclosed |
| EP-2086939-B1 | PYRIDINE CARBOXAMIDES AS 11-BETA-HSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2010-07-28 | — | — | EP | disclosed |
| CN-101787016-A | Pyridine carboxamides as the 11-beta-HSD 1 inhibitors | ASTRAZENECA AB | 2010-07-28 | — | — | CN | disclosed |
| US-20090312372-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-17 | — | — | US | disclosed |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2009-12-10 | — | — | US | disclosed |
| CN-101573336-A | Pyridine carboxamides as 11-beta-HSD 1 inhibitors | ASTRAZENECA AB (SE) | 2009-11-04 | — | — | CN | disclosed |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312372-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A12 3512/4885HSD11B1 1/4885FABP4 1288/4885 |
| US-20080269288-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A12 3512/4885HSD11B1 1/4885FABP4 1288/4885 |
| US-20090306075-A1 | CHEMICAL COMPOUNDS | HSD11B1, CYP11B1, CYP4A11 | SLC6A12 3512/4885HSD11B1 1/4885FABP4 1288/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.